{
  "eval_id": "S31",
  "eval_file": "evals/single/S31.json",
  "timestamp": "2025-09-18T17:14:39.582028+00:00",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy is indicated for adults with ER-positive, HER2-negative metastatic breast cancer who have received endocrine therapy and at least two prior systemic therapies, including a CDK4/6 inhibitor. Efficacy and safety are based on the label and the TROPiCS-02 trial; please review the EMA SmPC or EPAR for full details. If you can email the specific SmPC section, Iâ€™ll review it further."
}